We have seen a steady increase in the use of blood based biomarkers, the conversion rates from diagnosis ... ejection fraction indication for Tirzepatide. We believe the positive Phase 3 data ...

Thousands of Delhi residents are facing uncertainty as the Land and Development Office has halted leasehold to freehold property conversions for two and a half years, missing court-committed ...

May 2 (Reuters) - The U.S. Food and Drug Administration has accepted Novo Nordisk's (NOVOb.CO), opens new tab marketing application for an oral version of its weight-loss drug Wegovy and will ...

(Reuters) -The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its weight-loss drug Wegovy ... Lilly's injectable tirzepatide is sold ...

A huge market for compounded versions of Wegovy and rival therapy Zepbound (tirzepatide) from Eli Lilly sprang up while the two drugs were having supply constraints, with both companies trying to ...

Novo Nordisk has been almost single-handedly rebuilding the market for obesity drugs in recent years, with its GLP-1 agonist drugs Wegovy (semaglutide) and Saxenda (liraglutide), and tirzepatide ...

CVS Health announced plans to drop Eli Lilly's Zepbound from its preferred coverage in favor of Novo Nordisk A/S's Wegovy for weight ... on obesity, and tirzepatide... is gaining a lot of market ...

Novo Nordisk NOVO.B-3.93%decrease; red down pointing triangle said the Food and Drug Administration accepted its submission of a new drug application for a Wegovy pill to treat obesity amid a ...

The weight loss drug Wegovy treated a serious form of liver disease in about two-thirds of patients in a major clinical trial, according to the findings published Wednesday in the New England ...

Mounjaro (brand name for tirzepatide) also came onto the market in early 2024. Like Wegovy, tirzepatide stems from a drug originally designed to treat diabetes. The weekly injection helped ...

Eli Lilly has reported $12.73bn in Q1 2025 revenue, a 45% increase from the prior year, driven largely by demand for its diabetes and obesity drugs, Mounjaro (tirzepatide) and Zepbound ...